TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, Oct. 22 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) announces today a distribution
agreement with PL Thomas & Co., Inc. ("PLT") for the sale and marketing of its
ingredient XP-828L for the United States market.
Advitech and PLT, a major U.S. distributor of active ingredients for
nutraceutical, cosmeceutical and functional foods industries, have concluded a
non-exclusive distribution agreement with a yearly commitment for Advitech's
XP-828L ingredient, a patent-pending composition consisting of growth factors,
especially TGF- B2, capable to maintain healthy cytokines levels and to
support inflammatory process.
"The agreement with PLT is significant as it is an important player in
several segments of the American market targeted by Advitech" stated Mr. Luc
Clouâtre, Vice-President Business Development, Sales and Marketing at
Advitech. Mr. Clouâtre further added, "PL Thomas has strong market visibility
and existing business with many of the leading companies in the food and
dietary supplements industry". PLT has an excellent understanding of the
markets targeted by Advitech, and it will present the XP-828L to the U.S.
market this week at the Supply Side West ("SSW") ingredients show. Product
information will be displayed at the PLT booth, and Paul Flowerman, its
President, will discuss this ingredient in his speech, an official part of the
cosmeceutical track of the SSW educational program.
Other products of the Advitech portfolio, as well as several new
innovations, could be added in the Advitech-PLT agreement upon further
ABOUT PL THOMAS http://www.plthomas.com:
PL Thomas, a New Jersey-based ingredients supplier, offers fifty years of
innovation in internationally sourcing reliable, high quality raw materials
for the food and beverage, functional food, dietary supplements, and
nutricosmetic industries. PLT is a one-stop resource for application
solutions, current industry information and technical service, and
specializing in branded and clinically supported natural ingredients, notably
ABOUT ADVITECH http://www.advitech.com/:
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in inflammatory
process by maintaining healthy cytokines levels. Advitech produces Dermylex(R)
that helps reduce scaly and itchy skin and helps maintain healthy skin.
Advitech has drawn up a research program to develop new applications
related to wound healing. This development is derived from both its XP-828L
and IM technological platforms.
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
firstname.lastname@example.org; Serge Comeau, Investor's relations, (514) 862-4160,